Why Farbe Firma is the Top Manufacturer of Buprenorphine HCl Injection
- Maulik Sudani
- Jun 9
- 7 min read
Last Updated: June 9, 2026
TL;DR: Buprenorphine HCl Injection — a sterile aqueous solution of buprenorphine hydrochloride, a highly potent partial mu-opioid receptor agonist, supplied commonly as a 0.3 mg/mL solution in 1 mL ampoules for slow intravenous or intramuscular administration — is a cornerstone agent for the management of moderate to severe pain, including post-operative and peri-operative pain and pain where a long-acting opioid is required. Buprenorphine binds the mu-opioid receptor with high affinity and dissociates slowly, giving prolonged analgesia with a ceiling on respiratory depression, but its very high potency means each low-concentration ampoule must deliver an exact, sterile, particulate-free dose, and because it is an internationally scheduled narcotic its manufacture demands not only pharmaceutical quality but also rigorous controlled-substance custody, reconciliation and security. Its safety depends on a precise stability-indicating assay and content uniformity, a tightly controlled impurity and degradation profile, light protection, low particulate and endotoxin, correctly held pH and robust ampoule container-closure integrity, all under a fully auditable narcotic-control chain. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Buprenorphine HCl Injection at our Gujarat, India facility under appropriate narcotic licensing and supplies it to hospital pharmacy, anaesthesia, surgical, pain-management and palliative-care services, government tenders, licensed distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Potent partial mu-opioid receptor agonist analgesic — Buprenorphine HCl Injection manages moderate to severe pain, including post-operative and peri-operative pain and situations needing prolonged opioid analgesia, delivering high-affinity, long-acting, titratable pain relief with a ceiling on respiratory depression by the slow intravenous or intramuscular route.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified light-protected ampoule filling lines, dedicated control of the stability-indicating assay, the impurity profile, pH, content uniformity, particulate and endotoxin for a low-concentration, high-potency opioid injection, with container-closure integrity verification on every batch — all operated under controlled-substance custody and reconciliation.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary, narcotic-board and institutional tenders.
End-to-end CDMO services: Licensed controlled-substance contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready ampoule packaging and import/export permit coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Buprenorphine HCl Injection Demands a Premium Manufacturer
Buprenorphine HCl Injection occupies a cornerstone place in anaesthesia, surgery, pain management and palliative care across every market. It is the potent partial-agonist opioid that clinicians reach for when pain is moderate to severe and prolonged, high-affinity analgesia is needed — in post-operative and peri-operative pain, in chronic and cancer-related pain, and where a long duration of action and a ceiling on respiratory depression are clinically valuable. Given by slow intravenous or intramuscular injection, it provides potent, long-lasting and dose-adjustable pain relief. In each of these settings the dose delivered from each small, low-concentration ampoule must be exact, sterile and reliably the same from unit to unit, because with a drug this potent even tiny variations in delivered dose matter.
That clinical reality places real demands on the manufacturer — and buprenorphine adds a second layer those demands rarely face elsewhere. As an internationally scheduled narcotic, its manufacture requires licensed handling, secured storage, milligram-level reconciliation of active and finished units, and a fully auditable custody chain alongside the usual pharmaceutical controls. Chemically, buprenorphine hydrochloride is formulated at a very low concentration and is light-sensitive, so content uniformity and assay precision are unusually demanding and the solution must stay clear, correctly potent and free of degradation products across shelf life. The assay must be exact; the impurity and degradation profile must stay within tight limits; the solution must be particulate-free, low in endotoxin, held at the right slightly acidic pH and protected from light, then sealed in an ampoule whose integrity is verified. Choosing a Buprenorphine HCl Injection manufacturer that treats the stability-indicating assay, content uniformity, light protection, impurity profiling, particulate and endotoxin control, container-closure integrity and narcotic-custody compliance as core disciplines is what protects the patient — and the supply chain — at the point of care.
What Sets a World-Class Buprenorphine HCl Injection Manufacturer Apart
A world-class manufacturer of Buprenorphine HCl Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of buprenorphine with the content uniformity and tight related-substance and degradation-product control by HPLC that a high-potency, low-concentration solution demands, robust aseptic filling of a light-sensitive aqueous solution into ampoules with verified container-closure integrity, and a licensed, fully auditable controlled-substance custody system layered over tender-ready dossier support for a product procured through hospital-formulary, narcotic-board and ministry-of-health channels. It starts with the active — pharmacopoeial-grade buprenorphine hydrochloride sourced from licensed, qualified, audited narcotic API makers, received under secured, reconciled custody, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and sealing then have to protect both the assay and the dose. The bulk solution is compounded in water-for-injection at controlled slightly acidic pH with dextrose for tonicity, sterile-filtered through 0.22 µm membrane and filled aseptically into ampoules under light-protected ISO Class 5 conditions, with nitrogen overlay where the formulation requires it. The filling, content-uniformity and sealing parameters are locked in the master batch record, because for a high-potency opioid the assay, content uniformity and degradation-product profile govern both the efficacy and the safety of every ampoule. Each ampoule is fusion-sealed and 100 % inspected for particulate matter, fill volume, seal quality and cosmetic defects; in-process and release testing confirm buprenorphine assay and content uniformity by validated HPLC, the related-substance profile, pH and clarity of the solution, and endotoxin is held well within limits so the injection is safe for slow intravenous or intramuscular administration — while every milligram of active and every finished ampoule is reconciled through the controlled-substance ledger.
Quality Systems Behind Every Buprenorphine HCl Injection
Every Farbe Firma Buprenorphine HCl Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay and content uniformity of buprenorphine against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, pH and osmolarity, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, fill-volume verification and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to the narcotic API lot, the primary-packaging lot and the qualified person responsible for release — and reconciled against the controlled-substance custody record.
Around those release tests sits a deeper quality and security architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, light-protected (low-actinic) compounding and filling areas, calibrated sterilisation and depyrogenation equipment, validated ampoule filling lines with 100 % inspection, secured controlled-substance vaults with access control and milligram-level reconciliation, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because buprenorphine is high-potency and light-sensitive and its assay and content uniformity drive both efficacy and shelf life, we treat the stability-indicating HPLC assay, content uniformity and the degradation result as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light through amber glass and its secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Buprenorphine HCl Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across analgesic, anaesthetic, critical-care, anti-infective and supportive-care categories. For Buprenorphine HCl Injection specifically, we supply 0.3 mg/mL solution in 1 mL ampoules under WHO-GMP conditions and appropriate narcotic licensing, with country-specific strengths, fill volumes, tamper-evident packs and pack configurations available under controlled-substance contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, content-uniformity and impurity data package — ready to hand for registration, narcotic-board approval and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement, with the added controlled-substance layer handled in-house. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay, content-uniformity and related-substances method-validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate the import/export permits, narcotic-control documentation, shipping and logistics that a scheduled opioid requires. When a buyer needs Buprenorphine HCl Injection at tender scale our regulatory, manufacturing, narcotic-compliance and logistics teams move as one: dossier, validation reports, permits, light-protected artwork, filling-line slot and secured shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness, narcotic-compliance discipline and communication. Customer and regulatory auditors are welcomed onto the plant floor, into the filling suite and into the controlled-substance vault records; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through licensed API sourcing, stability-indicating assay and content-uniformity development, related-substance control, light-protection strategy, pH and tonicity, particulate and endotoxin control, container-closure integrity, narcotic reconciliation and shelf-life choices in real detail. For a potent, internationally controlled partial-agonist opioid where assay accuracy, content uniformity, light protection and an unbroken custody chain directly govern both patient safety and supply-chain integrity, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Buprenorphine HCl Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Buprenorphine HCl Injection under appropriate narcotic licensing at a Gujarat, India facility with ISO Class 5 aseptic processing, light-protected filling, qualified ampoule filling lines, qualified water-for-injection systems, secured controlled-substance custody, 100 % ampoule inspection and continuous environmental monitoring.
Which strengths and pack sizes of Buprenorphine HCl Injection do you supply?
Our standard presentation is a 0.3 mg/mL sterile aqueous solution in 1 mL ampoules. Custom strengths, fill volumes, tamper-evident ampoule counts per pack and country-specific artwork are available under controlled-substance contract manufacturing agreements.
How does Farbe Firma handle the controlled-substance requirements for Buprenorphine HCl Injection?
As an internationally scheduled narcotic, buprenorphine is manufactured under appropriate licensing with secured, access-controlled vaults, milligram-level reconciliation of active and finished units, a fully auditable custody chain, and coordination of import/export permits and narcotic-board documentation alongside the standard WHO-GMP pharmaceutical controls.
Can Farbe Firma support country-specific registrations for Buprenorphine HCl Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay, content-uniformity and related-substances method-validation data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations, narcotic-board approval and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia, subject to applicable narcotic import/export controls.
What is the minimum order quantity for Buprenorphine HCl Injection contract manufacturing?
MOQs vary by strength, ampoule size, fill volume, label complexity, dossier requirements and applicable narcotic-licensing conditions. For our ampoule presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments